Transforming the treatment of
fibro-inflammatory diseases
Developer of first-in-class therapeutics targeting the IL-11 pathway
Our Focus
IL-11 signalling is a fundamentally important driver of fibrogenesis, organ dysfunction and inflammation across human fibrotic diseases.
Enleofen develops innovative, safe and highly effective therapeutics that address today’s biggest healthcare challenges.
Our Strategy
Our Pipeline
Enx108A is a first-in-class human antibody that targets IL-11. Treatment with ENx108A is anti-fibrotic, anti-inflammatory and reverses organ dysfunction across disease models.
Integrated human discovery and efficacy screening pipelines for all our products.
